| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Chief Medical Officer
1 company
Lebwohl David is an EVP, Chief Medical Officer at NTLA. Recent filings cover 0 purchases and 21 sales. Those positions are worth an estimated $1.5M at current prices.
Our model assigns Lebwohl David a strong insider score of 87/100, based on 10 past trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +53.7%.
Lebwohl David's largest disclosed position is in NTLA as EVP, Chief Medical Officer, worth about $1.5M. The recent filings there lean toward selling, a net 42,928 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | NTLA Intellia Therapeutics, Inc. | EVP, Chief Medical Officer | Sell | 11,903 | $9.21 | $109,626.63 | -8.9% | +41.9% | - | |
| Jan 3, 2025 | NTLA Intellia Therapeutics, Inc. | EVP, Chief Medical Officer | Sell | 9,557 | $12.18 | $116,404.26 | -9.8% | -43.2% | -24.1% | |
| Jan 3, 2024 | NTLA Intellia Therapeutics, Inc. | EVP, Chief Medical Officer | Sell | 5,843 | $29.46 | $172,134.78 | -9.7% | -14.9% | -58.6% | |
| Jan 4, 2023 | NTLA Intellia Therapeutics, Inc. | EVP, Chief Medical Officer | Sell | 2,574 | $37.21 | $95,778.54 | -9.1% | -7.5% | -24.6% | |
| Jan 1, 2022 | NTLA Intellia Therapeutics, Inc. | EVP, Chief Medical Officer | Sale+OE | 1,051 | $112.24 | $117,964.24 | -8.8% | -35.6% | -70.7% | |
| Nov 5, 2021 | NTLA Intellia Therapeutics, Inc. | EVP, Chief Medical Officer | Sale+OE | 2,400 | $132.72 | $318,534.60 | -6.1% | -30.2% | -62.4% | |
| Oct 14, 2021 | NTLA Intellia Therapeutics, Inc. | EVP, Chief Medical Officer | Sale+OE | 2,400 | $128.44 | $308,249.11 | -4.8% | -25.7% | -60.3% | |
| Sep 21, 2021 | NTLA Intellia Therapeutics, Inc. | EVP, Chief Medical Officer | Sale+OE | 2,400 | $149.81 | $359,544.00 | -75.2% | -17.0% | -59.7% | |
| Aug 30, 2021 | NTLA Intellia Therapeutics, Inc. | EVP, Chief Medical Officer | Sale+OE | 2,400 | $158.04 | $379,300.00 | -21.0% | -27.4% | -60.9% | |
| Aug 9, 2021 | NTLA Intellia Therapeutics, Inc. | EVP, Chief Medical Officer | Sale+OE | 2,400 | $164.05 | $393,720.00 | -75.2% | -15.1% | -62.3% |